Results of the eCO trial published in the Journal of Clinical Oncology Informatics

Voluntis (the “Company” or “Voluntis” – ticker: VTX – ISIN Code: FR 0004183960), a company specialized in digital therapeutics, today announces that results for eCO, the digital therapeutic it developed for women with ovarian cancer in partnership with AstraZeneca and the National Cancer Institute, have been published in the Journal of Clinical Oncology (JCO®) Clinical Cancer Informatics.

The study, published as “Technology APPlications: Use of digital health technology to enable drug development,” examined the feasibility, usability and perceived satisfaction with eCO (eCediranib-Olaparib), a mobile application for side effect monitoring and reporting, in women with recurrent ovarian cancer. The eCO app was specifically designed to assist in managing acute treatment-related events such as hypertension and diarrhea, which are most often associated with treatment discontinuation, the need for drug holidays or dose interruptions/modifications. Users logged their data and received real-time treatment recommendations for their symptom management. Their data was also sent simultaneously to their care team who could follow their progress remotely via a web portal.

Symptoms reported via eCO allowed rapid provider response and a positive overall patient experience. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application. Patients indicated eCO use made them feel more involved in their care and better connected to their healthcare team.

The publication of these positive clinical results in the JCO® Clinical Cancer Informatics journal suggests there is increasing interest for digital adoption in oncology care,” said Pierre Leurent, CEO of Voluntis. “We design solutions to help people with cancer to better manage their side effects while they stay connected to their care team. We believe that digital therapeutics will one day become part of routine clinical oncology practice.” 

AstraZeneca and Voluntis formed a partnership in 2015, in collaboration with the NCI, to develop an innovative digital solution to support women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib.

About Voluntis

Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team that so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real-time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics. These include Insulia® and Diabeo® in diabetes as well as eCO and ZEMY in oncology. Voluntis has long-standing partnerships with leading life science companies such as Roche, AstraZeneca, Sanofi and Onduo. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. 

For further information:

 About AstraZeneca 

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Contact presse